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In the treatment of chronic hepatitis B (CHB), the ultimate goal is
preventing hepatitis B virus (HBV)-associated liver disease,
including hepatocellular carcinoma (HCC). Recently published
studies show that in CHB patients treated with the currently rec-
ommended ﬁrst-line nucleos(t)ide analogs (NAs) entecavir or
tenofovir, annual HCC incidences range from 0.01% to 1.4% in
non-cirrhotic patients, and from 0.9% to 5.4% in those with cirrho-
sis. In Asian studies including matched untreated controls, cur-
rent NA therapy consistently resulted in a signiﬁcantly lower
HCC incidence in patients with cirrhosis, amounting to an overall
HCC risk reduction of 30%; in non-cirrhotic patients, HCC risk
reduction was overall 80%, but this was only observed in some
studies. For patients of Caucasian origin, no appropriate com-
parative studies are available to date to evaluate the impact of
NA treatment on HCC. Achievement of a virologic response under
current NA therapy was associated with a lower HCC risk in
Asian, but not Caucasian studies. Studies comparing entecavir
or tenofovir with older NAs generally found no difference in
HCC risk reduction between agents, except for one study which
used no rescue therapy in patients developing lamivudine resis-
tance. Overall, these data indicate that with the current, potentJournal of Hepatology 20
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Despite the dramatic improvement in the management of chron-
ic hepatitis B (CHB), hepatocellular carcinoma (HCC) remains a
major cause of morbidity and mortality, accounting for around
350,000 deaths worldwide every year [1,2]. Natural history stud-
ies in untreated patients have reported annual HCC incidences of
0.3–0.6% in non-cirrhotic patients, and 2.2–3.7% in compensated
cirrhotic patients, with the highest rates observed in Asia [2].
The mechanism of hepatitis B virus (HBV)-related hepatocar-
cinogenesis is thought to involve several factors [3–5]. HBV DNA
sequences integrate into the host genome, which may down-
regulate tumor suppressor genes. Recent studies have shown that
integrated HBV is more frequent in HCCs than in adjacent liver
tissue, with host integration sites located at cancer-related genes,
including the telomerase reverse transcriptase (TERT) gene, and
viral breakpoints detected near the HBx gene [6,7]. The viral pro-
tein HBx may modulate the activity of several cellular factors
regulating cell proliferation, apoptosis, and DNA damage
response. Fibrosis and mainly cirrhosis, resulting from CHB-asso-
ciated persistent liver inﬂammation, trigger a complex cascade of
oxidative stress, hypoxia, necrosis, regeneration, and angio-
genesis, which may alter host gene expression.
Epidemiologic studies have conﬁrmed sustained viral replica-
tion and liver injury as key risk factors for HBV-related HCC, with
serum HBV DNA levels directly correlating with the future risk of
HCC [8,9]. Speciﬁc variations in the HBV DNA sequence, such as
HBV genotype C and basal core promoter (BCP) mutations have
also been associated with a higher HCC risk [10–12]. In addition15 vol. 62 j 956–967
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to these viral factors, older age, male gender, heavy alcohol con-
sumption, exposure to carcinogens such as aﬂatoxin B, a family
history of HCC, and more recently, elevated levels of quantitative
HBsAg (qHBsAg). Metabolic syndrome associated with obesity
and diabetes mellitus have also been established as risk factors
of HBV-related HCC [2,13–15]. Many of these factors are directly
or indirectly related to viral replication, which becomes a logical
target for HCC prevention.
Until recently, evidence of reduction of HCC incidence with
antiviral treatment had been limited to the older nucleos(t)ide
analogs (NAs) lamivudine and adefovir. The ﬁrst important data
to demonstrate the efﬁcacy of anti-HBV therapy in HCC risk
reduction are those from the randomized controlled trial by Liaw
et al. which compared lamivudine vs. placebo in NA-naive
patients with cirrhosis or advanced ﬁbrosis and active liver dis-
ease. After an early trial termination with a mean treatment
duration of approximately 3 years, lamivudine reduced the HCC
risk compared with placebo by 51% (HCC incidence 3.9% vs.
7.4%), offering a beneﬁt of marginal statistical signiﬁcance (haz-
ard ratio [HR] = 0.49; p = 0.047) [16]. Similar results were report-
ed in other studies with older NAs. In a systematic review
assessing mostly lamivudine (sometimes adefovir or the combi-
nation of both) vs. no treatment in NA-naive CHB patients, HCC
incidence rates over a follow-up of 4 years were reduced in treat-
ed patients (2.8%) compared with untreated patients (6.4%;
p = 0.003) [17]. A more recent meta-analysis also reported HCC
rates of 3.4% in lamivudine-treated vs. 9.6% in untreated CHB
patients over a follow-up of 4 years [18].
The NAs entecavir and tenofovir, currently recommended as
ﬁrst-line options for the treatment of CHB [19–21], maintain
long-term viral suppression in over 95% of patients, improve liver
histology, and often reverse histologic cirrhosis [22–24]. Howev-
er, their effect on HCC risk remains unclariﬁed. This review sum-
marizes recent studies assessing HCC development with these
current NAs, mainly entecavir due to data availability, and
explores whether mathematical models to estimate the HCC risk
may be applicable to the management of CHB patients at risk of
HCC.
Key Points
• Hepatocellular carcinoma (HCC) may still develop in 
chronic hepatitis B (CHB) patients treated with oral 
antiviral agents
• In CHB patients treated with the currently recommended 
first-line antivirals entecavir or tenofovir, the observed 
HCC risk ranges from 0.01 to 1.4% in patients without 
cirrhosis, and from 0.9 to 5.4% in those with cirrhosis 
• In Asian studies including matched untreated controls, 
treatment, and particularly treatment-induced virologic 
remission, with entecavir or tenofovir has been shown 
to reduce the risk of CHB-related HCC 
• To date, there are no appropriate comparative studies 
evaluating the impact of these agents on HCC in CHB 
patients of Caucasian origin 
• Accurate predictors or calculators of HCC risk under 
anti-HBV treatment may facilitate patient counseling 
and would be of great practical valueJournal of Hepatology 201Impact of entecavir and tenofovir on HBV-related HCC
Recently, several studies have been published that assessed out-
comes of HCC in patients treated with the NAs entecavir or teno-
fovir. In the following, we will review those reports that were
published in English up to July 2014 (Supplementary Table 1).
For published papers, PubMed was searched using the terms
‘HCC’, ‘hepatocellular carcinoma’, ‘hepatitis B’, ‘HBV’, ‘antiviral
therapy’, ‘entecavir’, or ‘tenofovir’; in addition, a manual search
for AASLD and EASL 2012–2014 conference abstracts was per-
formed using the same search terms. Studies were included in
this review if they involved a minimum of 100 patients, used
entecavir or tenofovir, and either had a control arm or, if sin-
gle-arm, reported separate HCC rates for cirrhotic and non-cir-
rhotic patients. Potential reports selected in the literature
search were evaluated by a second reviewer to determine
whether they fulﬁlled the inclusion criteria. Most of the studies
included in this review involved entecavir, which has been avail-
able for CHB treatment longer than tenofovir. Of these studies,
none was a randomized trial, but most were observational stud-
ies reporting HCC outcomes in entecavir-treated patients using as
control either untreated patients, or patients treated with one of
the older NAs lamivudine or adefovir.
HCC incidence under entecavir or tenofovir vs. no treatment
Five studies, all from East Asia, compared HCC incidence rates in
patients receiving current NAs (mostly entecavir) with those in
historical untreated control groups (Table 1) [25–29]. However,
such studies are limited by potential differences in baseline char-
acteristics that may affect the HCC risk in the two arms. Three of
these studies have utilized propensity score (PS) matching of the
cohorts to reduce these confounding effects [26,28,29].
Of the three studies using PS-matched controls, only the study
by Hosaka et al. from Japan included a cohort treated exclusively
with entecavir [26], while the other two studies assessed patients
treated with several NAs including entecavir [28,29]. In the study
by Hosaka et al. 25–29% of patients had pre-existing cirrhosis at
baseline [26]. The cumulative 5-year HCC incidence in the overall
patient population was signiﬁcantly lower with entecavir (3.7%)
than with no treatment (13.7%; p <0.001), with a >60% reduction
in HCC risk (adjusted HR = 0.37; p = 0.03) [26]. When the analysis
was stratiﬁed by the presence of cirrhosis, entecavir reduced the
HCC risk more than 4-fold in cirrhotic patients (cumulative 5-
year HCC incidence: 7.0% vs. 38.9%; p <0.001), whereas the differ-
ence was much more modest and non-signiﬁcant in non-cirrhotic
patients (cumulative 5-year HCC incidence 2.5% vs. 3.6%; p = 0.44)
[26]. Kumada et al. (Japan) used a treated cohort including
patients receiving entecavir (61%) or lamivudine with or without
adefovir (39%), and a PS-matched cohort of untreated patients.
The overall 5-year HCC incidence was signiﬁcantly lower with
NA therapy than without (2.7% vs. 11.3%; p <0.01), with a risk
reduction of >70% (HR = 0.28; p <0.01) [28]. A nationwide study
from Taiwan (Wu et al.) assessed PS-matched cohorts of NA-
treated patients (27% entecavir, 60% lamivudine, 1% telbivudine,
12% combination therapy) and patients receiving no NA therapy
but hepatoprotective agents (e.g. silymarin, liver hydrolysate, or
choline bitartrate). The 7-year HCC incidence was signiﬁcantly
lower in the NA-treated cohort (7.3%) than in the untreated
cohort (22.7%) (adjusted HR = 0.37; p <0.001). The beneﬁcial
effect of NA treatment was apparent in both patients with and5 vol. 62 j 956–967 957
Table 1. HCC outcomes in treated vs. untreated patients.
Study Treatment N Follow-up, yr, 
median (range)
HCC incidence, %* HCC with vs. without NA treatment
3-yr 5-yr 7-yr All pts Cirrhosis No cirrhosis
Hosaka [26]
(Japan)
NA-naive
Historical, PS-
matched control
ETV Total: 316
No cirrhosis: 237
Cirrhosis: 79
3.3 (2.3–4.3) 1.2
0
4.3
3.7
2.5
7
n.r. 5-year incidence
3.7% vs. 13.7%
p <0.001
HR = 0.37
p = 0.03
5-year incidence
7.0% vs. 38.9%
p <0.001
5-year incidence
2.5% vs. 3.6%
p = 0.44
No tx Total: 316 
No cirrhosis: 231
Cirrhosis: 85
7.6 (3.4–13.7) 7.2
1.6
20.9
13.7
3.6
38.9
n.r.
Wong [25] 
(Hong Kong)
NA-naive and  
experienced
Historical control
ETV Total: 1446 
No cirrhosis: 984
Cirrhosis: 482
3.0† 3.9
1.4
9.1
6.6
3.3
13.8
n.r. 5-year incidence
6.6% vs. 6.5%
5-year incidence
13.8% vs. 26.4%
p = 0.036
HR = 0.55
p = 0.049
5-year incidence
3.3% vs. 3.0%
No tx Total: 424
No cirrhosis: 355
Cirrhosis: 69
9.5† 3.7
1.7
14.5
6.5
3.0
26.4
n.r.
Su [27]
(Taiwan)
NA-naive
Historical control
ETV Cirrhosis: 666 
(all comp)
2.7† 2.4 n.r. n.r. n.r. 2.7-year incidence
2.4% vs. 5.2%
p = 0.009
HR = 0.41
 n.r.     
No tx Cirrhosis: 621 
(all comp)
9.1† 5.2 n.r. n.r.
Kumada [28]
(Japan)
NA-naive
Historical, PS-
matched control
NAs (61% 
ETV, 15% 
LVD, 24% 
LVD+ADV)
Total: 117 
No cirrhosis: 69 
Cirrhosis: 48
12.3 (3.1–19.4) n.r. 2.7 3.3 10-year incidence
3.3% vs. 40.0%
p = 0.0094
HR = 0.28
p = 0.002
n.r. n.r.
No tx Total: 117
No cirrhosis: 73
Cirrhosis: 44
11.6 (3.1–18.3) n.r. 11.3 26.0
Wu [29]
(Taiwan)
 (Previous 
treatment 
exposure not 
specified)
Historical, PS-
matched control
NAs 
(27% ETV, 
60% LVD, 
1% LdT, 
12% comb); 
hepato-
protective 
agents
Total: 21,595
No cirrhosis: 18,748
Cirrhosis: 2847
3.34 (1.40–5.50) n.r. n.r. 7.3 7-year 
incidence
7.3% vs. 22.7%
HR = 0.37
p <0.001
HR = 0.72 HR = 0.27
Hepato-
protective 
agents
Total: 21,595
No cirrhosis: 18,579
Cirrhosis: 3016
6.51 (3.54–7.00) n.r. n.r. 22.7
Areas shaded in light-grey indicate consistent data. ⁄Data shown are for total study population, and if reported, for subgroups of patients with no cirrhosis and cirrhosis.
Mean. ADV, adefovir; comb, combination therapy; comp, compensated cirrhosis; ETV, entecavir; HCC, hepatocellular carcinoma; HR, hazard ratio; LdT, telbivudine; LVD,
lamivudine; NAs, nucleos(t)ide analogs; n.r., not reported; PS, propensity score; TDF, tenofovir; tx, treatment.
Reviewwithout cirrhosis (non-cirrhosis: HR = 0.27; cirrhosis: HR = 0.72)
[29].
The two studies comparing entecavir-treated patients and
untreated historical controls without detailed matching reported
signiﬁcant reduction in the HCC rates in cirrhotic patients. An
observational study from Hong Kong by Wong et al. assessed the
impact of entecavir vs. no treatment in a mixed population of
NA-naive and NA-experienced (30%) patients. Pre-existing cirrho-
sis was detected in 33% of entecavir-treated and in 16% of untreat-
ed patients. Although there was no signiﬁcant difference in HCC
incidence between entecavir-treated and untreated patients in
the overall comparison, when the analysis was stratiﬁed by cir-
rhosis, entecavir signiﬁcantly reduced the HCC incidence in cir-
rhotic (5-year incidence 13.8% vs. 26.4%; HR = 0.55; p = 0.049),
but not in non-cirrhotic patients (5-year incidence 3% in both
groups) [25]. An observational multi-center study in compensated
cirrhotics from Taiwan compared patients receiving ﬁrst-line
entecavir with an untreated historical control group. The HCC
incidence in the ﬁrst 2.7 years was 2.4% in the entecavir group
and 5.2% in the untreated group (p = 0.009), corresponding to an
HCC risk reduction by 60% (HR = 0.41; 95% CI 0.20–0.84) [27].958 Journal of Hepatology 201Another approach to assess the impact of NA therapy vs.
no treatment on HCC development is to compare the HCC
incidence observed in treated patients with that predicted by
a risk calculator. This method was used by Kim et al. [30],
who compared the HCC incidence reported in the global teno-
fovir Phase III studies in NA-naive patients with the HCC inci-
dence estimated by the Risk Estimation for Hepatocellular
Carcinoma in Chronic Hepatitis B (REACH-B) risk calculator
based on individual patients’ characteristics [31]. Among 641
patients included in these studies, there were 13 cases of
HCC over 6 years of tenofovir therapy. The 10th HCC case
occurred at 3.3 years, at which time the REACH-B model pre-
dicted 11.2 cases. Beyond that time point, there was a pro-
gressive divergence between the predicted and observed
number of HCC cases (standardized incidence ratio = 0.55
[95% conﬁdence interval 0.32–0.94] after a median follow-up
of 5.5 years) [30]. One limitation of this study is that the
REACH-B model was developed in Asian non-cirrhotic patients
[31], whereas the tenofovir trials included mostly white
patients (59% Whites, 30% Asians) and 28% cirrhotic patients
[24,32].5 vol. 62 j 956–967
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HCC incidence in relation to on-therapy virologic remission
An alternative way of assessing the impact of antiviral therapy on
HCC risk is to correlate the degree of viral suppression with sub-
sequent development of HCC. This approach has been used by
seven studies; four from East Asia and three from Europe (Table 2)
[25,33–38]. Of these, six used exclusively entecavir, whereas one
study also involved other NAs; in the latter study, all patients
were NA-naive, whereas in the other six, patients could be NA-
naive or NA-experienced.
The study in NA-naive patients came from Korea, and included
treatments with various NAs (73% entecavir, 5% lamivudine, 3.5%
clevudine, 18.7% with sequential or combination therapy), which
achieved a virologic response (VR) in 82.5% of patients. In addi-
tion, a control group of inactive HBV carriers (HBeAg-negative)
was included. Among treated patients, HCC incidence was sig-
niﬁcantly higher among those who did not achieve a VR than in
those who did (p = 0.028), with a signiﬁcant treatment effect
observed in the subgroup of cirrhotic patients (p = 0.004), but
not in non-cirrhotics. However, treated patients with a VR still
had a signiﬁcantly higher HCC risk compared with inactive carri-
ers (overall annual HCC incidences 2.3% vs. 0.3%; p <0.001) [35].
Similar ﬁndings were observed in the Asian studies including
both NA-naive and NA-experienced patients. In a Taiwanese
cohort study of entecavir-treated patients (Yang et al.; 33.6%
NA-experienced; 40% cirrhotic), the cumulative incidences of
HCC were lower with achievement of a VR in both non-cirrhotic
(HR = 0.08; p = 0.001) and cirrhotic patients (HR = 0.21; p = 0.001)
[33]. In another study from Korea by Kim et al. including ente-
cavir-treated cirrhotic CHB patients, VR was associated with a
signiﬁcantly lower probability of developing HCC (HR = 0.06;
p <0.001) [34]. The Hong Kong study by Wong et al. described
earlier reported that in the entecavir group, virologic remission
had no impact on the HCC rate in the overall patient population
(8.7% vs. 10.7%, p = 0.33), but was associated with a signiﬁcantly
reduced probability of HCC in the subgroup of cirrhotic patients
(p = 0.02) [25].
In Caucasian CHB patients, the beneﬁt of virologic remission
was controversial. A large European study (VIRGIL) evaluated
entecavir-treated patients (23% NA-experienced; 22% cirrhotic;
42% Caucasian, 29% Asian, 29% other/unknown) [37]. After a fol-
low-up of 1.7 years, patients achieving a VR to entecavir had a
71% lower probability of a clinical event (HCC, hepatic decompen-
sation, or death) than those who did not (HR = 0.29; p = 0.05),
with a signiﬁcantly reduced risk among cirrhotic patients
(HR = 0.22; p = 0.04), but not in those without cirrhosis [36].
However, after prolonged follow-up to year 3, an association
between virologic suppression and HCC (HR = 0.87; p = 0.87) or
clinical event (HR = 0.70; p = 0.46) in the overall study population
was no longer observed [37]. Finally, in a study from Greece
including NA-naive or NA-experienced patients treated with
entecavir, virologic remission was achieved in 97% of cases and
was reported not to affect the HCC incidence, but the number
of patients without remission was rather small [38].
HCC incidence under entecavir or tenofovir vs. older NAs
Seven studies addressed whether entecavir or tenofovir are more
effective in reducing HCC risk than older NAs (Table 3). Four of
these studies were from East Asia [26,39–41], two from Turkey
[42,43], and one from Greece [38]. The study by Hosaka et al. inJournal of Hepatology 201NA-naive patients also included a comparison between ente-
cavir-treated patients and historical controls receiving lamivudine
without any rescue therapy upon resistance (182 PS-matched
patients in each group); in non-cirrhotic patients, HCC rates were
comparable between entecavir and lamivudine; however, in
cirrhotic patients, the HCC incidence was signiﬁcantly lower with
entecavir than with lamivudine (p = 0.04) [26]. The study by
Kobashi et al. from Japan included NA-naive patients treated with
entecavir or lamivudine (47% with rescue therapy; baseline cir-
rhosis 22% and 27%, respectively). After a treatment duration of
4 years, there was no signiﬁcant difference in the overall HCC
incidence between entecavir and lamivudine. However, lamivu-
dine resistance, which developed in 60/127 (47%) lamivudine-
treated patients, was associated with a signiﬁcantly increased
risk of HCC (20.3% vs. 3.2% at year 5; p = 0.04; [39]). A Korean
analysis of PS-matched pairs of NA-naive patients treated with
entecavir or lamivudine (39% with rescue therapy) found that
in the overall study population, and in patients with cirrhosis,
the risk of death or transplantation was 50–60% lower with ente-
cavir than with lamivudine (p <0.001) after 3 years of follow-up;
however, HCC risk over the same time period was comparable
between the two treatments. In patients without cirrhosis, there
was no difference between treatments for both outcomes [40].
Another Korean study in patients treated with either entecavir
or lamivudine (proportion of patients with rescue therapy not
reported) also found no signiﬁcant difference in HCC incidence
between entecavir (6.5%) and lamivudine (7.3%) after 2.5 years
of therapy (p = 0.131), despite higher rates of undetectable HBV
DNA and lower resistance with entecavir [41].
An ongoing nationwide study in Greece (HEPNET) assessed
HCC incidence in a mixed (24% NA-experienced; 25% cirrhotic)
cohort of HBeAg-negative patients treated with entecavir, com-
pared with that in an historical cohort of lamivudine-treated
patients (49% with rescue therapy). In the overall population,
HCC incidence was lower with entecavir than with lamivudine
(2.8% vs. 5.6% at year 5; p = 0.024), but the difference could not
reach statistical signiﬁcance when the treatment effect was
evaluated separately in non-cirrhotic patients (0.5% vs. 3.2% at
year 5; p = 0.091) and cirrhotic patients (9.3% vs. 11.5% at year
5; p = 0.277). In a multiple regression analysis, HCC risk was
not associated with antiviral agent type [38]. A Turkish study
(Köklü et al.) assessed the impact of entecavir, tenofovir, and
lamivudine (32% with rescue therapy) in NA-naive and -experi-
enced (14%) patients with cirrhosis. Over 3 years of follow-up,
the HCC incidence was comparable between the three agents
[42]. In another Turkish study comparing NAs with a high (ente-
cavir or tenofovir) or low (lamivudine or adefovir; proportion of
patients with rescue therapy not reported) genetic barrier, HCC
development was signiﬁcantly associated with low genetic barri-
er drug regimens (p = 0.02) and resistance-associated virologic
breakthrough (p = 0.04) [43].
Summary of annual HCC rates under entecavir or tenofovir
The annual HCC rates under entecavir or tenofovir reported in
these studies, and in single-arm studies assessing HCC outcomes
during treatment with these NAs [44–46], are shown separately
for non-cirrhotic and cirrhotic patients in Fig. 1A and B. In non-
cirrhotic patients treated with entecavir or tenofovir, annual
HCC incidences ranged from 0.0% to 1.4% in Asian patients, and
from 0.1% to 1.0% in predominantly Caucasian populations. In cir-5 vol. 62 j 956–967 959
Table 2. HCC outcomes in treated patients with vs. without virologic response.
Study Treatment N Follow-up, 
yr, median 
(range)
VR* HCC incidence, %† HCC with vs. without NA treatment
3-yr 5-yr 7-yr All pts Cirrhosis No cirrhosis
Wong [25] 
(Hong Kong)
Tx-naive +  
-experienced
ETV Total: 1446 
No cirrhosis: 984
Cirrhosis: 482
3.0‡ + VR: 77% 8.7 n.r. n.r. 3-year incidence
8.7% vs. 10.7% 
p = 0.33
3-year incidence
p = 0.02
n.r.
– VR: n.r. 10.7 n.r. n.r.
Yang [33]
(Taiwan)
Tx-naive +  
-experienced
ETV Total: 323
No cirrhosis: 202
Comp cirrhosis: 106
Decomp cirr: 15
3.0 (1.0–6.0) + VR: 83-98% n.r. n.r. n.r. n.r. HR = 0.08
p = 0.001
HR = 0.21
p = 0.001– VR: n.r. n.r. n.r. n.r.
Kim [34]
(Korea)
Tx-naive +  
-experienced
ETV Cirrhosis: 324
Comp cirrhosis: 220
Decomp cirr: 104
3.0‡ + VR: n.r. n.r. n.r. n.r. n.r. RR = 0.056
p <0.001
n.r.
– VR: n.r. n.r. n.r. n.r.
Cho [35]
(Korea)
Tx-naive
NAs (73% 
ETV, 5% LVD, 
22% other)
Total: 1378
No cirrhosis: 933
Cirrhosis: 445
3.3‡ + VR: 82% 5.9
4.7
8.1
11.4
7.2
17.4
n.r. 5-year incidence
11.4% vs. 18.8%
p = 0.028
5-year incidence
17.4% vs. 38.7% 
p = 0.004
5-year incidence
7.2% vs. 11.1%
p = 0.212
– VR: 18% 8.6
6.4
14.3
18.8
11.1
38.7
n.r.
Zoutendijk [36]
(Europe)
Tx-naive +  
-experienced
ETV Total: 372
No cirrhosis: 274
Comp cirrhosis: 98
1.7 (0.9–2.7) + VR: 93% n.r. n.r. n.r. HR  = 0.29
p = 0.05
HR = 0.22
p = 0.04
HR = 0.24
p = 0.27
– VR: n.r. n.r. n.r. n.r.
Arends [37]
(Europe)
Tx-naive +  
-experienced
ETV Total: 744 
No cirrhosis: 580 
Cirrhosis: 164
3.2 (1.6–4.1) + VR: 99% n.r. n.r. n.r. HR = 0.87
p = 0.87
n.r. n.r.
– VR: n.r. n.r. n.r. n.r.
Papatheodoridis 
[38]
(Greece)
Tx-naive +  
-experienced
ETV Total: 321
No cirrhosis: 212
Comp cirrhosis: 55
Decomp cirr: 14
Unclassified: 40
3.3 (2.1–4.3) + VR: 97% n.r. n.r. n.r. 5-year incidence 
n.s.
n.r. n.r.
– VR: n.r. n.r. n.r. n.r.
Areas shaded in light-grey indicate consistent data. ⁄Data shown are for total study population. Data shown are for total study population, and if reported, for subgroups of patients with no cirrhosis and cirrhosis.
Mean. ADV, adefovir; cirr, cirrhosis; comb, combination therapy; comp, compensated cirrhosis; decomp: decompensated cirrhosis; ETV, entecavir; HCC, hepatocellular carcinoma; HR, hazard ratio; LdT, telbivudine;
LVD, lamivudine; NAs, nucleos(t)ide analogs; NR, not reported; PS, propensity score; RR, risk reduction; TDF, tenofovir; tx, treatment; VR, virologic response.
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Table 3. HCC outcomes with current NAs vs. older NAs.
Study Treatment N Follow-up, yr;
median (range)
HCC incidence, %* HCC with current vs. older NAs
3-yr 5-yr 7-yr All pts Cirrhosis No 
cirrhosis
Hosaka [26]
(Japan)
Tx-naive
Historical, PS-
matched control
ETV
(rescue 
therapy: none)
Total: 316
No cirrhosis: 237
Cirrhosis: 79
3.3 (2.3–4.3) 1.2
0
4.3
3.7
2.5
7.0
n.r. 5-year 
incidence
7.0% vs. 
22.2%
p = 0.043
5-year 
incidence
7.0% vs. 
22.2%
p = 0.043
5-year 
incidence
2.5% vs. 
4.9%
p = 0.126
LVD 
(rescue 
therapy: none)
Total: 182
No cirrhosis: 97
Cirrhosis: 85
6.8 (5.0–9.9) n.r.
3.2
12.2
n.r.
4.9
22.2
n.r.
Kobashi [39]
(Japan) 
Tx-naïve
ETV
(rescue 
therapy: <1%)
Total: 129
No cirrhosis: 101
Cirrhosis: 28
2.9 (0.4–7.5) 7.0 11.8 n.r. 5-year 
incidence
11.8% vs. 
11.7% 
p = 0.680
n.r. n.r.
LVD
(rescue 
therapy: 47%)
Total: 127
No cirrhosis: 93
Cirrhosis: 34
6.0 (0.5–10.0) 6.4 11.7 n.r.
Lim [40]
(Korea)
PS-matched
Tx-naive +  
-experienced
ETV
(rescue 
therapy: 1.8%)
Total: 1792
No cirrhosis: 878
Cirrhosis: 860
3.1 (2.2–4.3) n.r. n.r. n.r. Annual 
incidence
2.4% vs. 
2.5%
HR = 1.01
p = 0.95
Annual 
incidence
4.1% vs. 
4.35% 
HR = 1.0
p = 0.999
Annual 
incidence
0.7% vs. 
0.8%
HR = 1.26
p = 0.46
LVD
(rescue 
therapy: 39.3%)
Total: 1792
No cirrhosis: 878
Cirrhosis: 860
8.7 (6.5–11.5) n.r. n.r. n.r.
Lee [41]
(Korea)
Previous tx not 
specified
ETV
(rescue 
therapy: n.r.)
Total: 293 2.5 6.5% (yr 2.5) n.r. n.r. 2.5-year 
incidence
6.5% vs. 
7.3%
p = 0.131
n.r. n.r.
LVD
(rescue 
therapy: n.r.)
Total: 165 2.4 7.3% (yr 2.4) n.r. n.r.
Papatheodoridis 
[38]
(Greece)
Tx-naive +  
-experienced
Historical 
control
ETV
(rescue 
therapy: <1%)
Total: 321
No cirrhosis: 212
Comp cirrhosis: 55
Decomp cirr: 14
Unclassified: 40
3.3 (2.2–4.3) 1.2
0.5
-
2.8
0.5
-
n.r. 5-year 
incidence
2.8% vs. 
5.6%
p = 0.024
HR = 1.9
p = 0.214
5-year 
incidence
9.3% vs. 
11.5%
p = 0.277
5-year 
incidence
0.5% vs. 
3.2%
p = 0.091
LVD  
(rescue 
therapy: 49%)
Total: 818
No cirrhosis: 517
Comp cirrhosis: 160
Decomp cirr: 56
Unclassified: 85
4.7 (2.6–6.4) 3.8
1.7
  
-
5.6
3.2
- 
n.r.
Goturk [43]
(Turkey)
Previous tx 
exposure not 
specified
ETV or TDF
(rescue 
therapy: NA)
Total: 661
No cirrhosis: 436
Cirrhosis: 225
4 (1–7.8) n.r. n.r. n.r. Low barrier 
to resistance 
agent
p = 0.02‡
Resistance/ 
virologic 
breakthrough 
p = 0.04‡
n.r. n.r. 
LVD or ADV 
(rescue 
therapy: NA)
n.r. n.r. n.r.
Köklü [42]
(Turkey)
Tx-naive +  
-experienced
ETV
(rescue 
therapy: 2.6%)
Total: 77
No cirrhosis: 0
Comp cirrhosis: 41
Decomp cirr: 36
2.0† 4/77** (yr 2) n.r. n.r. n.r. n.r. n.r.
TDF
(rescue 
therapy: 2.7%)
Total: 72
No cirrhosis: 0
Comp cirrhosis: 46
Decomp cirr: 26
1.8† 2/72** (yr 1.8) n.r. n.r.
LVD
(rescue 
therapy: 32%)
Total: 74
No cirrhosis: 0
Comp cirrhosis: 34
Decomp cirr: 40
3.0† 6/74** (yr 3) n.r. n.r.
8.5               11.5
3.3               9.3
Areas shaded in light-grey indicate consistent data. ⁄Data shown are for total study population, and if reported, for subgroups of patients with no cirrhosis and cirrhosis.
Mean. Multivariate regression analysis. ⁄⁄n/N.
ADV, adefovir; comb, combination therapy; comp, compensated cirrhosis; decomp: decompensated cirrhosis; ETV, entecavir; HCC, hepatocellular carcinoma; HR, hazard
ratio; LdT, telbivudine; LVD, lamivudine; NA, not assessed; NAs, nucleos(t)ide analogs; PS, propensity score; RR, risk reduction; TDF, tenofovir; tx, treatment.
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Fig. 1. Annual HCC incidence rates with entecavir or tenofovir in CHB without cirrhosis (A) and with cirrhosis (B). Annual HCC incidences were calculated from studies
with different follow-up duration by assuming constant incidence rates over time. In panel B, the following studies reported rates for compensated cirrhotic patients only
(decompensated excluded): Wong [25,53]; Yang, naive/experienced cohort [33]; Lampertico, ETV cohort [44]; Papatheodoridis, ETV/TDF cohort [54]. The following studies
reported pooled rates for patients with compensated and decompensated cirrhosis, with the ratio of decompensated and compensated given in brackets: Yang, NA-naive
cohort (15/106) [33]; Kim (104/220) [34]; Papatheodoridis, ETV cohort (14/55) [38]; Köklü, ETV cohort (36/41), TDF cohort (26/46) [42]. In the following studies the number
of any decompensated patients that may have been included in the cirrhotic cohort is not reported: Hosaka [26]; Chen [46]; Lim [40]; Cho [35]; Su [27]; Wu [29].
⁄Proportions of Caucasian patients included in the study populations were: Lampertico, ETV cohort: >98% [Lampertico personal communication]; Lampertico, TDF cohort:
100% [Lampertico personal communication]; Arends: 42.5% [37]; Papatheodoridis ETV cohort >98% [Papatheodoridis personal communication], ETV/TDF cohort: 99.2% [54];
Köklü: not reported. (CHB, chronic hepatitis B; ETV, entecavir; HCC, hepatocellular carcinoma; n.r., not reported; TDF, tenofovir; tx, treatment).
Reviewrhotic patients treated with entecavir or tenofovir, HCC rates
were around 4 to 5 times higher than in those without cirrhosis,
ranging from 0.9% to 5.4% in Asians and from 1.5% to 5.2% in Cau-
casians. HCC rates in NA-naive patients were comparable to those
in mixed populations of NA-naive and -experienced patients. This
observation is in line with a Taiwanese study (Chen et al.) which
assessed the HCC outcomes under entecavir in cirrhotic patients962 Journal of Hepatology 201based on previous treatment exposure; HCC incidence was com-
parable between NA-naive and NA-experienced patients (15.8%
vs. 11.1%; p = 0.98) [46].
Using those studies that assessed outcomes with and without
NA treatment [25–27,29], all of which were Asian and with
entecavir, we also compared the mean annual HCC incidences
weighted according to the sample size of each study. In patients5 vol. 62 j 956–967
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with cirrhosis, the weighted mean annual HCC incidence was
3.2% with entecavir compared with 4.5% without treatment
(p = 0.004); in patients without cirrhosis, the weighted mean
annual HCC incidences with and without treatment were 0.68%
and 2.90% (p <0.0001), respectively. When considering only stud-
ies with a PS-matched control [26,29], the weighted mean annual
HCC incidences were 3.83% with entecavir compared with 5.0%
without treatment (p = 0.028) in patients with cirrhosis, and
0.68% vs. 2.94% (p <0.0001) in those without cirrhosis.Risk calculators for HBV-related HCC
Several scoring systems, most of which were derived from data
on untreated Asian patients, have been developed to predict the
risk of HBV-related HCC based on some of the known HCC risk
factors (Table 4, [31,47–49]). The REACH-B score was based on
data from the Taiwanese Risk Evaluation of Viral Load ElevationTable 4. Comparisons of published risk scoring systems for HCC.
CU-HCC
(Wong et al.) [47]
GAG-HCC  
(Yuen et al.) [48]
Number of patients 1005 820
Place of development Hong Kong Hong Kong
Ethnicity Asian Asian
Age (years) 48.0 40.6
HBeAg-negative (%) Not reported 56.6
Cirrhosis (%) 38.1 15.1
Follow-up (years) 9.94 5.62
Antiviral therapy (%) 15.1 0
HCC (n, %) 105, 10.4 40, 4.9
Scoring system Variable Points Variable Points
Age 
>50 years 3
Age
Per year 1 (1*)
Albumin 
<3.5 g/dl
20 Male 16 (14*)
Bilirubin
>1.1 mg/dl 1.5
BCP 
mutation
19 
Cirrhosis 15 Cirrhosis 30 (33*)
HBV DNA
4–6 log
>6 log
1
4
HBV DNA
Per log 3 (3*)
Risk scores Low (<5), intermediate  
(5–20), and high (>20)
Low (<101) and  
high (≥101)
⁄Simpliﬁed GAG-HCC score excluding core promoter mutations. The risk score attributed
ml because most patients with HBV DNA P106 copies/mL were also HBeAg-positive,
transferase; BCP, basal core promoter; CU-HCC, Chinese University – Hepatocellular C
mutations and Cirrhosis; HCC, hepatocellular carcinoma; REACH-B, Risk Estimation for
copies/ml.
Journal of Hepatology 201and Associated Liver Disease (REVEAL) cohort, and was subse-
quently validated in other independent Asian patient groups
[31]. A revised version of REACH-B exists that also integrates
serum qHBsAg levels [50]. Two other Asian scoring systems,
Chinese University – Hepatocellular Carcinoma score (CU-HCC)
(including 15% treated patients) and Guide with Age, Gender,
HBV DNA, Core promoter mutations and Cirrhosis (GAG-HCC),
have been developed using data from two independent Hong
Kong cohorts [47,48]. The latter two models highlight that cir-
rhosis is an important risk factor for HCC in Asians; although
without a biopsy, detection of cirrhosis in routine practice is
neither sensitive nor standardized [51]. Non-invasive measure-
ments of liver ﬁbrosis such as transient elastography may
enhance the accuracy of these models; however, further studies
are needed [52].
An important question is whether HCC risk predictors are also
applicable in patients receiving antiviral therapy, as this general-
ly results in HBV DNA suppression and sometimes also regressionREACH-B
(Yang et al.) [31]
PAGE-B
(Papatheodoridis et al.) [49]
3584 1619
Taiwan Europe 
Asian Caucasian
45.7 53
84.8 84
0 30
12.0 3.3
0 100 
131, 3.7 56, 3.5
Variable Points Variable Points 
Age
Per 5 years 
over 30 
1
Age
<30
30–39
40–49
50–59
60–69
≥70
–4
–2
0
2
4
6
Male 2 Male 5
ALT, U/L
15–44
≥45
1
2
Platelets, mm3
≥200x103
100–<200x103
<100x103
0
6
11
HBeAg-positive 2
HBV DNA
<4 log
4–<5 log
5–<6 log
≥6 log
0
3
5
4†
A 17-point risk scale A 27-point risk scale (–4 to 22); 
low (<6), intermediate (6–10), and 
high (>10)
to HBV DNAP106 copies/ml was less than that for HBV DNA of 105–<106 copies/
thus sharing the associated higher score for this category. ALT, alanine amino-
arcinoma score; GAG-HCC, Guide with Age, Gender, HBV DNA, Core promoter
Hepatocellular Carcinoma in Chronic Hepatitis B. HBV DNA presented as log10
5 vol. 62 j 956–967 963
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of cirrhosis [19–21]. The accuracy of REACH-B, CU-HCC, and GAG-
HCC has been conﬁrmed in entecavir-treated patients in one
cohort from Hong Kong, and seems to increase from year 2 of
therapy onwards compared with baseline [53]. However, these
models were reported to offer poor accuracy for the prediction
of HCC in European Caucasian patients receiving antiviral therapy
[37,54]. In mostly Caucasian European patients under entecavir
or tenofovir therapy, a new score named PAGE-B has recently
been developed; in this score, which included age, gender, and
platelet counts probably reﬂecting the severity of liver disease,
the addition of cirrhosis did not substantially improve the dis-
crimination [49].
The variables included in all these models can be conceptually
divided into three categories: (i) variables that are readily modiﬁ-
able by antiviral therapy, namely HBV DNA and alanine amino-
transferase (ALT); (ii) variables that can potentially be altered
with long-term antiviral therapy, namely albumin, bilirubin, pla-
telets, HBeAg status, and, ultimately, cirrhosis; and (iii) variables
that are not affected, namely age and gender. Examination of the
weights associated with these variables may be instructive in
estimating the impact on HCC risk that could potentially be
attributed to antiviral therapy by the different risk scores. The
CU-HCC model, in which four out of the ﬁve variables are modiﬁ-
able by NAs, may suggest that most of the HCC risk may be
eliminated with effective long-term antiviral therapy. In the
GAG-HCC model, the relative impact on HCC risk of reversible
components is much smaller. With the REACH-B score, out of
the possible maximum score of 17, up to nine are potentially
reversible. In PAGE-B, only one (platelets) of the three variables
may be altered with antiviral therapy. Serum HBV DNA is includ-
ed in three of the four models, and is also an important compo-
nent of guideline recommendations to determine treatment
candidacy [19–21]. In general, recent studies investigating pre-
dictors of HCC under NA therapy usually identiﬁed older age
(P50–60 years), cirrhosis or advanced liver disease, male gender,
family history of HCC, and previous lamivudine therapy as risk
factors for HCC during NA therapy [37,38,55,56]. Importantly,
baseline HBV DNA level was not associated with HCC risk
[35,56], which is in contrast to studies assessing HCC risk in
untreated patients [8,9], and highlights the importance of differ-
ent HCC risk models for different patient populations.Discussion
The data summarized in this review show that treatment with
the current NAs entecavir and tenofovir can reduce the risk of
HCC, which is consistent with prior data from the lamivudine
era. The treatment effect was signiﬁcant in patients with cirrho-
sis, whereas a signiﬁcant HCC risk reduction in non-cirrhotic
patients was noticeable only in some reports. Using only studies
reporting comparative data with vs. without NA treatment, all of
which were from Asia, treatment with a current NA resulted in a
signiﬁcant reduction of HCC risk by 30% in cirrhotic patients,
and by 80% in non-cirrhotic patients. Although the data are lim-
ited, no substantial difference seemed evident between treat-
ment-naive and -experienced patients.
The putative mechanisms of how antiviral therapy reduces
HCC risk may include downregulation of hepatic inﬂammation
and related nuclear signaling pathways that lead to neoplastic
transformation at the cellular level, as well as reversal of ﬁbrosis964 Journal of Hepatology 201and reduction of regenerative stimuli at the tissue level. Antiviral
therapy may also reduce expression of HBx protein to levels
insufﬁcient to promote HCC development, or act at a genomic
level by preventing HBV DNA integration into host chromosomes
or affecting its malignant potential [3–5].
The fact that antiviral therapy reduces HCC risk in cirrhotic
patients is remarkable considering that cirrhosis is regarded as
a pre-malignant condition [57]. Both entecavir and tenofovir have
been shown to achieve reversal of cirrhosis over treatment peri-
ods of around 5 years [23,24]. However, the effect of antiviral
therapy on HCC incidence in some of the studies appears to
become evident before a signiﬁcant amount of ﬁbrosis regression
is expected, which may suggest that some elements in the car-
cinogenesis process may be driven independently of histologic
liver damage [58], as also evidenced by cases of HCC develop-
ment in the absence of prior cirrhosis [59].
Regarding the HCC risk in patients without cirrhosis, ﬁndings
were inconsistent between studies, with a signiﬁcant treatment-
induced risk reduction reported in some [29,33], but not in other
reports [25,26,35]. The lack of treatment effect in non-cirrhotic
patients may be due to insufﬁcient statistical power relating to
the lower HCC incidence in these patients, and a relatively short
follow-up. On the other hand, one of the studies which observed
a reduced HCC incidence in non-cirrhotic patients [29] reported a
relatively high HCC incidence in the untreated control group
(approximately 3% annually), similar to that reported in cirrhotic
patients of other studies; in addition, there were some differ-
ences in baseline characteristics between treated and untreated
non-cirrhotic patients, indicating that these results may have to
be interpreted with caution. Thus, for non-cirrhotic patients,
more studies with longer follow-ups are needed to provide con-
clusive evidence regarding the effect of treatment on HCC.
For patients of Caucasian origin, no comparative study assess-
ing HCC outcomes with and without NA therapy is currently
available. One recent US study comparing PS-matched cohorts
of treated and untreated cohorts demonstrated an overall risk
reduction with anti-HBV therapy of 60%, but the type of NAs used
was not speciﬁed [60]. A number of single-arm studies assessed
HCC outcomes in Caucasian patients treated with entecavir- or
tenofovir. Comparing HCC data from these studies (annual rates
in non-cirrhotic patients: 0.1–1.0%; cirrhotic patients: 1.5–5.2%)
with those previously published in natural history studies (annu-
al rates in non-cirrhotic patients: 0.3%; cirrhotic patients: 2.2%
[2]), it appears that in Caucasian patients, NA treatment has little
or no impact on HCC reduction in both patients with and without
cirrhosis. However, such comparisons need to be interpreted cau-
tiously due to possible differences in patient characteristics
between different cohorts (particularly due to inclusion of older
patients in the most recent cohorts). More studies with appropri-
ate controls are needed to establish the impact of NA therapy on
HCC in patients of Caucasian origin.
When comparing treated patients of different ethnicities, it
appeared that annual HCC incidences were comparable between
Asian and mixed-ethnicity populations. This is in contrast with
previous reports in untreated patients showing 2–3-fold higher
HCC rates in Asians [2,61]. However, such comparisons are again
difﬁcult because of different patient characteristics, including dif-
ferences in the criteria for treatment indication and
reimbursement.
Regarding the association of virologic suppression and HCC
development, conﬂicting results have been reported. In Asian5 vol. 62 j 956–967
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studies, achievement of a VR was associated with a lower HCC
risk, in particular among patients with cirrhosis; however this
could not consistently be conﬁrmed in European studies, which
is in agreement with a previous report in Caucasian patients
treated with lamivudine [62]. The inconsistency might be
explained by differences in the patient population such as HBV
genotype distribution. In addition, a difﬁculty with this type of
analysis is the generally small number of patients without viro-
logic suppression and HCC cases during potent antiviral therapy
with entecavir or tenofovir. However, it might also be that just
the achievement of a VR is not sufﬁcient for reducing HCC risk.
For example, it has been reported that the duration of VR to
NAs was signiﬁcantly associated with HCC risk (P24 months:
HR = 0.10) [55], whereas other studies found that HCC risk reduc-
tion was associated with treatment-induced HBsAg seroclearance
[63], or reduction in HBV DNA and qHBsAg levels (HBsA-
g <100 IU/ml) [64].
The fact that achievement of virologic suppression per se is not
necessarily associated with a reduced HCC risk may also explain
why most studies comparing entecavir or tenofovir with older
NAs did not observe a difference in HCC risk reduction between
agents. In most of these studies, 30–50% of the lamivudine-treat-
ed patients were switched to entecavir or tenofovir. The only
report which did observe a signiﬁcantly greater HCC risk reduc-
tion with entecavir than with lamivudine is the study by Hosaka
et al. [26], where no rescue therapy was used (as it was not avail-
able for this historical control cohort). Several studies found that
HCC development was signiﬁcantly associated with resistance
development, resistance-associated virologic breakthrough, low
genetic barrier drug regimen, and prior lamivudine exposure
[37,39,43]. These ﬁndings are consistent with earlier results from
Liaw et al. showing increased disease progression in patients with
lamivudine resistance [16], and suggest that incomplete viral
suppression that results in resistance and breakthrough-related
hepatic ﬂares can be a risk factor for HCC.Implications for clinical practice and future research
An important message that emerges from this review is that
although HCC risk can be reduced with the current NAs entecavir
and tenofovir, it cannot be eliminated (at least within several
years of therapy) due to risk factors that are not amenable to
change by antiviral therapy (such as family history of HCC, dura-
tion of the infection, or HBV genotype), or carcinogenic events
that may have taken place before treatment initiation (such as
prior treatment exposure and history, or integration of HBV
DNA into the host genome). Thus, HCC surveillance remains an
important component in the management of treated patients,
even if they maintain complete viral suppression. This is the con-
text in which valid HCC risk calculators may be useful. The tools
available today partially fulﬁll such goals to the extent that vari-
ables that are not modiﬁable by antiviral therapy can be identi-
ﬁed. In Asian patients, the REVEAL, CU-HCC, and GAG-HCC risk
calculators have been shown to be valid in one cohort of Asian
patients treated with entecavir [53]. A revised version of
REACH-B, incorporating liver stiffness values (by transient elas-
tography) instead of serum HBV DNA, has been shown to accu-
rately predict liver-related events among patients that achieve
a complete VR under NA treatment [65]. For Caucasian patients
receiving antiviral therapy, particularly entecavir or tenofovir,Journal of Hepatology 201the PAGE-B score appears to be the most suitable HCC risk predic-
tor [49]. Additional validated pre- and on-therapy calculators
derived from other patient populations would be of great practi-
cal value to inform best practice for HCC surveillance and to facil-
itate patient counseling. HCC risk scores may also be used to
complement treatment indications as recommended by current
CHB practice guidelines. For example, some patients whose
HBV DNA levels indicate an increased HCC risk based on HCC
scores may not be recommended for antiviral therapy by the
guidelines. In addition, qHBsAg levels, which have been shown
to correlate with HCC risk in some patients [13], may be integrat-
ed into HCC risk prediction and patient management [66].
Another important point is that all of the observational data
discussed in this review, as well as the data from the Liaw et al.
trial [16], were derived from a subset of CHB patients, namely
those who have evidence of active liver disease, and are at risk
of progression and future complications based on CHB treatment
guidelines. Therefore, the data in this review should not be con-
strued to indicate that HCC risk may be reduced in all patients
with HBV infection. For example, there has been no study to date
assessing the effect of antivirals on HCC risk in patients in the
immune-tolerant phase, or in HBeAg-negative patients with nor-
mal ALT but elevated HBV DNA levels.
In summary, accumulating evidence indicates that antiviral
therapy with the current NAs entecavir or tenofovir prescribed
to control hepatic inﬂammation and prevent or reverse liver
ﬁbrosis can also reduce the risk of HCC, especially in Asian
patients. Further studies are needed to describe the impact of
treatment in non-cirrhotic patients, and in patients of Cau-
casian ethnicity. Additional studies may also be justiﬁed to
investigate whether there are subgroups of patients who cur-
rently do not meet the treatment criteria, and yet may beneﬁt
from HCC risk reduction by being treated with potent antiviral
agents. Other future research opportunities may include
mechanistic studies to understand cellular processes in which
antiviral therapy may interfere with carcinogenesis. They may
inform the search for biomarkers and clinical predictors of
response, ultimately leading to individualized management of
HBV patients to optimize clinical beneﬁts of antiviral therapy
in reducing the risk of HCC as well as preventing and reversing
chronic liver disease.Conﬂict of interest
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